Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Status: | Recruiting |
---|---|
Conditions: | Blood Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - 39 |
Updated: | 2/23/2019 |
Start Date: | June 1, 2017 |
End Date: | August 2024 |
Contact: | Daniel J. DeAngelo, MD, PhD |
Email: | daniel_deangelo@dfci.harvard.edu |
Phone: | 617-632-2645 |
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin
and how well it works when given with frontline chemotherapy in treating patients with newly
diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab
ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used
in chemotherapy work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute
lymphoblastic leukemia.
and how well it works when given with frontline chemotherapy in treating patients with newly
diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab
ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used
in chemotherapy work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute
lymphoblastic leukemia.
PRIMARY OBJECTIVES:
I. To confirm tolerability of the combination regimen with the addition of inotuzumab
ozogamicin to the pediatric-inspired regimen of cancer and leukemia group B (CALGB) 10403.
II. To determine whether the addition of inotuzumab ozogamicin significantly improves the
event-free survival (EFS) in patients who achieve an induction response achieved with the
pediatric-inspired regimen of CALGB 10403, without censoring for transplant. (Phase III)
SECONDARY OBJECTIVES:
I. To determine the impact of inotuzumab ozogamicin on disease-free (DFS) and overall
survival (OS) in patients who achieve an induction response.
II. To determine whether the addition of inotuzumab ozogamicin significantly improves the
event-free survival (EFS) in patients who achieve an induction response achieved with the
pediatric-inspired regimen of CALGB 10403, with censoring for transplant.
III. To determine the impact of inotuzumab ozogamicin on minimal residual disease (MRD) and
correlate this with the EFS, DFS and OS.
IV. To determine the prognosis based on patients' low-density array (LDA) gene signature in
terms of EFS, DFS, and OS after treatment with or without inotuzumab ozogamicin when added to
the C10403 backbone regimen.
V. To evaluate the toxicity and tolerability of the addition of inotuzumab ozogamicin to the
pediatric-inspired regimen of CALGB 10403.
TERTIARY OBJECTIVES:
I. To assess both the correlation of MRD post-induction and at sequential timepoints with LDA
signature.
II. To evaluate the influence of MRD status (detectable vs. not and as a continuous measure)
in relation to EFS both in the univariate setting as well as adjusting for other clinical
features including initial white blood cell (WBC), ethnicity, gender and age at diagnosis.
III. To evaluate the impact of inotuzumab ozogamicin (inotuzumab) on the kinetics of MRD
during treatment with inotuzumab in patients randomized to the experimental treatment arm.
IV. To perform genomic analyses to identify and evaluate the incidence and clinical
significance of recurring novel fusion genes including those associated with the
BCR-ABL1-like signature and to correlate with MRD status, CR rate, EFS and OS.
V. To assess whether rs4958351 is correlated with L-asp allergic reaction in the adolescent
and young adult (AYA) population.
VI. To assess the incidence of inherited genetic variants in the GR1A1, CEP72, CPA2, TPMT,
NUDT15, GRIN3A, GRIK1, and other genes (which can be found using a whole genome association
study [GWAS]), are correlated with increased rates of target toxicities including peripheral
neuropathy, hepatotoxicity, pancreatitis, myelosuppression, neurotoxicity, thrombosis, and
osteonecrosis, and correlate with treatment discontinuation and other clinical response
parameters including complete response (CR) rate, EFS, and OS.
VII. To evaluate asparaginase pharmacokinetics in adolescents and young adults, and
investigate its correlation with toxicities and treatment outcomes.
VIII. To investigate the effect of anti-polyethylene glycol (PEG) and anti-agouti signaling
protein (ASP) antibodies (PEG-ASP) on ASP enzyme activity.
IX. To measure adherence to oral 6 mercaptopurine (MP) and methotrexate in AYAs with acute
lymphoblastic leukemia (ALL) and to examine sociodemographic and behavioral determinants of
adherence.
X. To determine the impact of adherence on risk of relapse among AYAs with ALL.
OUTLINE:
COURSE I (REMISSION INDUCTION THERAPY): All patients receive allopurinol orally (PO) once
daily until peripheral blasts and extramedullary disease are reduced and cytarabine
intrathecally (IT) over 1 minute on day 1. Patients also receive daunorubicin hydrochloride
intravenously (IV) and vincristine sulfate IV on days 1, 8, 15 and 22, dexamethasone PO or IV
twice daily (BID) on days 1-7 and 15-21, pegylated recombinant L-asparaginase erwinia
chrysanthemi IV on day 4, 5, or 6, and methotrexate IT over 1 minute on days 8 and 29.
Patients with central nervous system (CNS) 3 disease receive methotrexate IT over 1 minute
also on days 15 and 22. All patients then undergo bone marrow aspirate and biopsy on day 29.
Patients with response to remission induction therapy are randomized to 1 of 2 arms. Patients
with no response are omitted from the study.
ARM I:
COURSE II (REMISSION CONSOLIDATION CHEMOTHERAPY): Patients receive cyclophosphamide IV on
days 1 and 29, cytarabine IV or SC on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO on
days 1-14 and 29-42, and vincristine sulfate IV on days 15, 22, 43, and 50. Patients also
receive pegylated recombinant L- asparaginase erwinia chrysanthemi IV on days 15 and 43, and
methotrexate IT on days 1, 8, 15, and 22. Patients with CNS3 receive methotrexate IT only on
days 1 and 8. CD20 positive (+) patients receive rituximab IV on days 1, 8, 29, and 36.
Patients then undergo bone marrow aspirate and biopsy on day 56.
COURSE III (INTERIM MAINTENANCE CHEMOTHERAPY): Patients receive vincristine sulfate IV on
days 1, 11, 21, 31, and 41, methotrexate IV and IT on days 1, 11, 21, 31, and 41, and
pegylated recombinant L- asparaginase erwinia chrysanthemi IV on days 2 and 22. CD20+
patients receive rituximab IV on days 1 and 11.
COURSE IV (DELAYED INTENSIFICATION): Patients receive vincristine sulfate IV on days 1, 8,
15, 43, and 50, dexamethasone PO or IV BID on days 1-7 and 15-21, doxorubicin IV on days 1,
8, and 15, and pegylated recombinant L- asparaginase erwinia chrysanthemi IV on day 4, 5, or
6 and day 43. Patients also receive cyclophosphamide IV on day 29, cytarabine IV or SC on
days 29-32 and 36-39, thioguanine PO on days 29-42 and methotrexate IT on days 1, 29, and 36.
CD20+ patients receive rituximab IV on days 1 and 8. Patients then undergo bone marrow
aspirate and biopsy on day 50.
COURSE V (MAINTENANCE THERAPY): Patients receive vincristine sulfate IV on days 1, 29, and
57, dexamethasone PO or IV BID on days 1-5, 29-33, and 57-61, and mercaptopurine PO on days
1-84. Patients also receive methotrexate IT or PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64,
71, and 78. Treatment repeats every 12 weeks for up to 3 years in the absence of disease
progression or unacceptable toxicity.
ARM II: Patients receive inotuzumab ozogamicin IV on days 1, 8, and 15 and undergo bone
marrow aspirate and biopsy on day 28. Treatment repeats every 28 days for up to 2 courses in
the absence of disease progression or unacceptable toxicity. Patients also receive remission
consolidated chemotherapy, interim maintenance chemotherapy, delayed intensification, and
maintenance therapy as in Arm I.
After completion of study treatment, patients are followed up every month for the first year,
every 2 months for the second year, every 3 months for the third year, and every 6 months for
the fourth through tenth year.
I. To confirm tolerability of the combination regimen with the addition of inotuzumab
ozogamicin to the pediatric-inspired regimen of cancer and leukemia group B (CALGB) 10403.
II. To determine whether the addition of inotuzumab ozogamicin significantly improves the
event-free survival (EFS) in patients who achieve an induction response achieved with the
pediatric-inspired regimen of CALGB 10403, without censoring for transplant. (Phase III)
SECONDARY OBJECTIVES:
I. To determine the impact of inotuzumab ozogamicin on disease-free (DFS) and overall
survival (OS) in patients who achieve an induction response.
II. To determine whether the addition of inotuzumab ozogamicin significantly improves the
event-free survival (EFS) in patients who achieve an induction response achieved with the
pediatric-inspired regimen of CALGB 10403, with censoring for transplant.
III. To determine the impact of inotuzumab ozogamicin on minimal residual disease (MRD) and
correlate this with the EFS, DFS and OS.
IV. To determine the prognosis based on patients' low-density array (LDA) gene signature in
terms of EFS, DFS, and OS after treatment with or without inotuzumab ozogamicin when added to
the C10403 backbone regimen.
V. To evaluate the toxicity and tolerability of the addition of inotuzumab ozogamicin to the
pediatric-inspired regimen of CALGB 10403.
TERTIARY OBJECTIVES:
I. To assess both the correlation of MRD post-induction and at sequential timepoints with LDA
signature.
II. To evaluate the influence of MRD status (detectable vs. not and as a continuous measure)
in relation to EFS both in the univariate setting as well as adjusting for other clinical
features including initial white blood cell (WBC), ethnicity, gender and age at diagnosis.
III. To evaluate the impact of inotuzumab ozogamicin (inotuzumab) on the kinetics of MRD
during treatment with inotuzumab in patients randomized to the experimental treatment arm.
IV. To perform genomic analyses to identify and evaluate the incidence and clinical
significance of recurring novel fusion genes including those associated with the
BCR-ABL1-like signature and to correlate with MRD status, CR rate, EFS and OS.
V. To assess whether rs4958351 is correlated with L-asp allergic reaction in the adolescent
and young adult (AYA) population.
VI. To assess the incidence of inherited genetic variants in the GR1A1, CEP72, CPA2, TPMT,
NUDT15, GRIN3A, GRIK1, and other genes (which can be found using a whole genome association
study [GWAS]), are correlated with increased rates of target toxicities including peripheral
neuropathy, hepatotoxicity, pancreatitis, myelosuppression, neurotoxicity, thrombosis, and
osteonecrosis, and correlate with treatment discontinuation and other clinical response
parameters including complete response (CR) rate, EFS, and OS.
VII. To evaluate asparaginase pharmacokinetics in adolescents and young adults, and
investigate its correlation with toxicities and treatment outcomes.
VIII. To investigate the effect of anti-polyethylene glycol (PEG) and anti-agouti signaling
protein (ASP) antibodies (PEG-ASP) on ASP enzyme activity.
IX. To measure adherence to oral 6 mercaptopurine (MP) and methotrexate in AYAs with acute
lymphoblastic leukemia (ALL) and to examine sociodemographic and behavioral determinants of
adherence.
X. To determine the impact of adherence on risk of relapse among AYAs with ALL.
OUTLINE:
COURSE I (REMISSION INDUCTION THERAPY): All patients receive allopurinol orally (PO) once
daily until peripheral blasts and extramedullary disease are reduced and cytarabine
intrathecally (IT) over 1 minute on day 1. Patients also receive daunorubicin hydrochloride
intravenously (IV) and vincristine sulfate IV on days 1, 8, 15 and 22, dexamethasone PO or IV
twice daily (BID) on days 1-7 and 15-21, pegylated recombinant L-asparaginase erwinia
chrysanthemi IV on day 4, 5, or 6, and methotrexate IT over 1 minute on days 8 and 29.
Patients with central nervous system (CNS) 3 disease receive methotrexate IT over 1 minute
also on days 15 and 22. All patients then undergo bone marrow aspirate and biopsy on day 29.
Patients with response to remission induction therapy are randomized to 1 of 2 arms. Patients
with no response are omitted from the study.
ARM I:
COURSE II (REMISSION CONSOLIDATION CHEMOTHERAPY): Patients receive cyclophosphamide IV on
days 1 and 29, cytarabine IV or SC on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO on
days 1-14 and 29-42, and vincristine sulfate IV on days 15, 22, 43, and 50. Patients also
receive pegylated recombinant L- asparaginase erwinia chrysanthemi IV on days 15 and 43, and
methotrexate IT on days 1, 8, 15, and 22. Patients with CNS3 receive methotrexate IT only on
days 1 and 8. CD20 positive (+) patients receive rituximab IV on days 1, 8, 29, and 36.
Patients then undergo bone marrow aspirate and biopsy on day 56.
COURSE III (INTERIM MAINTENANCE CHEMOTHERAPY): Patients receive vincristine sulfate IV on
days 1, 11, 21, 31, and 41, methotrexate IV and IT on days 1, 11, 21, 31, and 41, and
pegylated recombinant L- asparaginase erwinia chrysanthemi IV on days 2 and 22. CD20+
patients receive rituximab IV on days 1 and 11.
COURSE IV (DELAYED INTENSIFICATION): Patients receive vincristine sulfate IV on days 1, 8,
15, 43, and 50, dexamethasone PO or IV BID on days 1-7 and 15-21, doxorubicin IV on days 1,
8, and 15, and pegylated recombinant L- asparaginase erwinia chrysanthemi IV on day 4, 5, or
6 and day 43. Patients also receive cyclophosphamide IV on day 29, cytarabine IV or SC on
days 29-32 and 36-39, thioguanine PO on days 29-42 and methotrexate IT on days 1, 29, and 36.
CD20+ patients receive rituximab IV on days 1 and 8. Patients then undergo bone marrow
aspirate and biopsy on day 50.
COURSE V (MAINTENANCE THERAPY): Patients receive vincristine sulfate IV on days 1, 29, and
57, dexamethasone PO or IV BID on days 1-5, 29-33, and 57-61, and mercaptopurine PO on days
1-84. Patients also receive methotrexate IT or PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64,
71, and 78. Treatment repeats every 12 weeks for up to 3 years in the absence of disease
progression or unacceptable toxicity.
ARM II: Patients receive inotuzumab ozogamicin IV on days 1, 8, and 15 and undergo bone
marrow aspirate and biopsy on day 28. Treatment repeats every 28 days for up to 2 courses in
the absence of disease progression or unacceptable toxicity. Patients also receive remission
consolidated chemotherapy, interim maintenance chemotherapy, delayed intensification, and
maintenance therapy as in Arm I.
After completion of study treatment, patients are followed up every month for the first year,
every 2 months for the second year, every 3 months for the third year, and every 6 months for
the fourth through tenth year.
Inclusion Criteria:
REGISTRATION ELIGIBILITY CRITERIA (STEP 1)
- Newly diagnosed patients with CD-22 positive B-cell acute lymphoblastic leukemia (WHO
criteria) are eligible. Patients with Burkitt type ALL are NOT eligible
- Patients who have BCR-ABL fusion transcript determined by fluorescence in situ
hybridization (FISH) or real time-polymerase chain reaction (RT-PCR) or
t(9;22)(q34;q11) by cytogenetics are not eligible and should be considered for
enrollment on studies that incorporate imatinib during induction; please note: flow
cytometry is to be performed at the local reference lab and must include assessment of
CD20 and CD22 positivity, as well as CD29 and CD22 anti-positivity
- No prior therapy except for limited treatment (< 7 days) with corticosteroids or
hydroxyurea and a single dose of intrathecal cytarabine
- No prior therapy for acute leukemia except emergency therapy (corticosteroids or
hydroxyurea) for blast cell crisis, superior vena cava syndrome, or renal failure due
to leukemic infiltration of the kidneys; when indicated, leukapheresis or exchange
transfusion is recommended to reduce the WBC
- Single-dose intrathecal cytarabine is allowed prior to registration or prior to
initiation of systematic therapy for patient convenience; systemic chemotherapy must
begin within 72 hours of this intrathecal therapy
- Patients receiving prior steroid therapy are eligible for study; the dose and duration
of previous steroid therapy should be carefully documented on case report forms
- Not pregnant and not nursing; for women of childbearing potential only, a negative
urine or serum pregnancy test done =< 7 days prior to registration is required
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Patients with down syndrome are excluded from this study
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x upper limit of
normal (ULN), unless suspected leukemic involvement of the liver
- Direct bilirubin =< 3 x upper limit of normal (ULN), unless suspected leukemic
involvement of the liver
- Calculated (calc.) creatinine clearance >= 50 mL/min by Cockcroft-Gault
RANDOMIZATION ELIGIBILITY CRITERIA (STEP 2)
- Completion of remission induction therapy
- Patients with M2 marrow or better are eligible; patients with M3 or M4 marrow (greater
than 25% lymphoblasts) will not be eligible to be randomized
- Rating: M0, M1; Blast Cells (%): 0-5.0
- Rating: M2; Blast Cells (%): 5.1-25.0
- Rating: M3; Blast Cells (%): > 25-50
- Rating: M4; Blast Cells (%): > 50.0
- The term "blast cell" includes any cell that cannot be classified as a more
mature normal element, and includes "leukemic cells," pathologic lymphocytes, and
stem cells
- No ascites, effusions or significant edema
- Absolute neutrophil count (ANC) >= 1,000/mm^3
- Platelet count >= 100,000/mm^3
- Total bilirubin =< 1.5 x upper limit of normal (ULN), except for patients with known
Gilbert's syndrome
- Aspartate aminotransferase (AST) =< 8 x upper limit of normal (ULN)
- Completion of first 12 weeks (12+ weeks) of maintenance therapy (Course V)
- Patient has at least 24 weeks (24+ weeks) remaining before end of maintenance therapy
(Course V)
- Patient is in complete continuous first remission at entry into A041501-HO1
- Patient is receiving oral anti-metabolite chemotherapy during the maintenance phase of
therapy; treatment plan must call for the following doses of antimetabolites: 6MP 75
mg/m2/day orally; methotrexate (MTX) 20 mg/m2/week orally (modification of 6 MP or MTX
dosing based on laboratory or clinical parameters is acceptable)
- Patient is able and willing to use the Medication Event Monitoring System (MEMS)
TrackCap (e.g. not using a pillbox)
We found this trial at
201
sites
1200 Pleasant Street
Des Moines, Iowa 50309
Des Moines, Iowa 50309
(515) 241-KIDS
Principal Investigator: Robert J. Behrens
Phone: 773-702-9171
Blank Children's Hospital Blank Children's Hospital is completely dedicated to meeting the unique health care...
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Daniel J. DeAngelo
Phone: 617-667-9925
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Eunice S. Wang
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
300 Community Drive
Manhasset, New York 11030
Manhasset, New York 11030
(516) 562-0100
Principal Investigator: Cristina M. Ghiuzeli
Phone: 516-734-8896
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Principal Investigator: Brandon M. Hayes-Lattin
Phone: 503-494-1080
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Danielle A. Shafer
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Paul M. Barr
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 773-702-9171
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Jennifer M. Suga
Phone: 877-642-4691
Click here to add this to my saved trials
1625 Maple Lane
Ashland, Wisconsin 54806
Ashland, Wisconsin 54806
Principal Investigator: Andrea M. Watson
Phone: 218-786-3308
Click here to add this to my saved trials
Ashland, Wisconsin 54806
Principal Investigator: Andrea M. Watson
Phone: 218-786-3308
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Rebecca B. Klisovic
Phone: 404-778-1868
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
Baltimore, Maryland 21201
410-328-7904
Principal Investigator: Ashkan Emadi
Phone: 800-888-8823
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: Laura E. Finn
Phone: 225-761-5346
Click here to add this to my saved trials
Baton Rouge, Louisiana 70816
Principal Investigator: Laura E. Finn
Phone: 225-761-5346
Click here to add this to my saved trials
Baton Rouge, Louisiana 70836
Principal Investigator: Laura E. Finn
Phone: 504-703-8712
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Alison K. Conlin
Phone: 360-715-4133
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Alison K. Conlin
Phone: 541-706-2909
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Alison K. Conlin
Phone: 773-702-9171
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Daniel J. DeAngelo
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
Boston, Massachusetts 02114
(617) 724-4000
Principal Investigator: Daniel J. DeAngelo
Phone: 877-726-5130
Massachusetts General Hospital Cancer Center An integral part of one of the world
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Brainerd, Minnesota 56401
Principal Investigator: Andrea M. Watson
Phone: 773-702-9171
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Alison K. Conlin
Phone: 818-847-4793
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: Daniel M. Anderson
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Centralia, Washington 98531
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
Principal Investigator: Matthew C. Foster
Phone: 877-668-0683
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: Wendy Stock
Phone: 773-702-8222
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
Click here to add this to my saved trials
1200 West Harrison Stree
Chicago, Illinois 60607
Chicago, Illinois 60607
(312) 996-4350
Principal Investigator: John G. Quigley
Phone: 312-355-3046
Univ of Illinois A major research university in the heart of one of the world's...
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Chicago, Illinois 60611
Principal Investigator: Shira N. Dinner
Phone: 312-695-1301
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
Chicago, Illinois 60612
(312) 942-5000
Principal Investigator: Melissa L. Larson
Phone: 312-942-5498
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
Click here to add this to my saved trials
9280 SE Sunnybrook Blvd #100
Clackamas, Oregon 97015
Clackamas, Oregon 97015
(503) 513-3300
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Clackamas Radiation Oncology Center State-of-the-art technology and compassionate care come together at Clackamas Radiation Oncology...
Click here to add this to my saved trials
Clovis, California 93611
Principal Investigator: Uzair B. Chaudhary
Phone: 559-256-9680
Click here to add this to my saved trials
Clovis, California 93611
Principal Investigator: Uzair B. Chaudhary
Phone: 559-387-1827
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Bhavana Bhatnagar
Phone: 800-293-5066
Click here to add this to my saved trials
4050 Coon Rapids Blvd NW
Coon Rapids, Minnesota 55433
Coon Rapids, Minnesota 55433
(763) 236-6000
Principal Investigator: Daniel M. Anderson
Phone: 952-993-1517
Mercy Hospital Mercy Hospital, located in Coon Rapids, Minnesota, is a 271-bed non-profit hospital that...
Click here to add this to my saved trials
Coos Bay, Oregon 97420
Principal Investigator: Alison K. Conlin
Phone: 541-269-8392
Click here to add this to my saved trials
10 Barnes West Drive
Creve Coeur, Missouri 63141
Creve Coeur, Missouri 63141
Principal Investigator: Geoffrey L. Uy
Phone: 800-600-3606
Click here to add this to my saved trials
115 10th Avenue Northeast
Deer River, Minnesota 56636
Deer River, Minnesota 56636
Principal Investigator: Andrea M. Watson
Phone: 218-786-3308
Click here to add this to my saved trials
Des Moines, Iowa 50309
Principal Investigator: Robert J. Behrens
Phone: 515-282-2921
Click here to add this to my saved trials
Des Moines, Iowa 50314
Principal Investigator: Robert J. Behrens
Phone: 515-282-2200
Click here to add this to my saved trials
1200 Pleasant St
Des Moines, Iowa 50309
Des Moines, Iowa 50309
(515) 241-6212
Principal Investigator: Robert J. Behrens
Phone: 515-241-6727
Iowa Methodist Medical Center Iowa Methodist Medical Center was established in 1901 in a single...
Click here to add this to my saved trials
700 E University Ave
Des Moines, Iowa 50316
Des Moines, Iowa 50316
(515) 263-5612
Principal Investigator: Robert J. Behrens
Phone: 515-241-8704
Iowa Lutheran Hospital Iowa Lutheran Hospital has a long history of serving the Des Moines...
Click here to add this to my saved trials
Detroit, Michigan 48236
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
1027 Washington Avenue
Detroit Lakes, Minnesota 56501
Detroit Lakes, Minnesota 56501
Principal Investigator: Andrea M. Watson
Phone: 773-702-9171
Click here to add this to my saved trials
Duluth, Minnesota 55805
Principal Investigator: Andrea M. Watson
Phone: 218-786-3308
Click here to add this to my saved trials
Duluth, Minnesota 55805
Principal Investigator: Andrea M. Watson
Phone: 888-203-7267
Click here to add this to my saved trials
Duluth, Minnesota 55805
Principal Investigator: Andrea M. Watson
Phone: 218-786-3308
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Jeffrey Crawford
Phone: 888-275-3853
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
East Stroudsburg, Pennsylvania 18301
Principal Investigator: Tareq Al Baghdadi
Phone: 570-422-1700
Click here to add this to my saved trials
6401 France Ave S
Edina, Minnesota 55435
Edina, Minnesota 55435
(952) 924-5000
Principal Investigator: Daniel M. Anderson
Phone: 952-993-1517
Fairview Southdale Hospital Fairview Health Services is an award-winning nonprofit health care system based in...
Click here to add this to my saved trials
Evanston, Illinois 60201
Principal Investigator: Lynne S. Kaminer
Phone: 847-570-2109
Click here to add this to my saved trials
1717 13th St
Everett, Washington 98201
Everett, Washington 98201
(425) 297-5500
Principal Investigator: Alison K. Conlin
Phone: 425-261-3529
Providence Regional Cancer Partnership Founded in 2007, the Providence Regional Cancer Partnership is the result...
Click here to add this to my saved trials
Fargo, North Dakota 58103
Principal Investigator: Andrea M. Watson
Phone: 218-786-3308
Click here to add this to my saved trials
Fergus Falls, Minnesota 56537
Principal Investigator: Andrea M. Watson
Phone: 218-786-3308
Click here to add this to my saved trials
302 Kensington Ave
Flint, Michigan 48503
Flint, Michigan 48503
(810) 762-8490
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Genesys Hurley Cancer Institute Bringing the most advanced cancer treatment services, technologies and programs available...
Click here to add this to my saved trials
900 Hilligoss Boulevard Southeast
Fosston, Minnesota 56542
Fosston, Minnesota 56542
Principal Investigator: Andrea M. Watson
Phone: 701-364-6272
Click here to add this to my saved trials
Fresno, California 93720
Principal Investigator: Jennifer M. Suga
Phone: 877-642-4691
Click here to add this to my saved trials
550 Osborne Rd NE
Fridley, Minnesota 55432
Fridley, Minnesota 55432
(763) 236-5000
Principal Investigator: Daniel M. Anderson
Phone: 952-993-1517
Unity Hospital Unity Hospital is one of the Twin Cities
Click here to add this to my saved trials
Fruitland, Idaho 83619
Principal Investigator: Alison K. Conlin
Phone: 773-702-9171
Click here to add this to my saved trials
Glenview, Illinois 60026
Principal Investigator: Lynne S. Kaminer
Phone: 847-570-2109
Click here to add this to my saved trials
1117 29th St S
Great Falls, Montana 59405
Great Falls, Montana 59405
(406) 771-7300
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Benefis Healthcare- Sletten Cancer Institute Benefis Hospitals has 516 beds at its two campuses (that...
Click here to add this to my saved trials
900 West Faris Rd.
Greenville, South Carolina 29605
Greenville, South Carolina 29605
(864)455-8898
Principal Investigator: Jeffrey K. Giguere
Phone: 773-702-9171
BI-LO Charities Children's Cancer Center The BI-LO Charities Children
Click here to add this to my saved trials
Greenville, South Carolina 29605
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
Click here to add this to my saved trials
Greenville, South Carolina 29615
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
Click here to add this to my saved trials
Greenville, South Carolina 29607
Principal Investigator: Howland E. Crosswell
Phone: 864-603-6213
Click here to add this to my saved trials
1 St. Francis Drive
Greenville, South Carolina 29601
Greenville, South Carolina 29601
864-255-1000
Principal Investigator: Howland E. Crosswell
Phone: 864-603-6213
Saint Francis Hospital This 245-bed, all-private-room facility is located near downtown Greenville, South Carolina. Formerly...
Click here to add this to my saved trials
Greer, South Carolina 29650
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
Click here to add this to my saved trials
Hartford, Connecticut 06105
Principal Investigator: Nikolai A. Podoltsev
Phone: 203-785-5702
Click here to add this to my saved trials
730 East 34th Street
Hibbing, Minnesota 55746
Hibbing, Minnesota 55746
Principal Investigator: Andrea M. Watson
Phone: 218-786-3308
Click here to add this to my saved trials
Highland Park, Illinois 60035
Principal Investigator: Lynne S. Kaminer
Phone: 847-570-2109
Click here to add this to my saved trials
Iowa City, Iowa 52242
Principal Investigator: Thomas H. Carter
Phone: 800-237-1225
Click here to add this to my saved trials
Issaquah, Washington 98029
Principal Investigator: Alison K. Conlin
Phone: 206-215-3086
Click here to add this to my saved trials
2430 20th Street Southwest
Jamestown, North Dakota 58401
Jamestown, North Dakota 58401
Principal Investigator: Andrea M. Watson
Phone: 701-364-6272
Click here to add this to my saved trials
1102 W 32nd St
Joplin, Missouri 64804
Joplin, Missouri 64804
(417) 347-1111
Principal Investigator: Jay W. Carlson
Phone: 417-347-4030
Freeman Health System Freeman in Joplin, Missouri, is a 485-bed, three-hospital system providing comprehensive healthcare...
Click here to add this to my saved trials
310 Sunnyview Ln
Kalispell, Montana 59901
Kalispell, Montana 59901
(406) 752-5111
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Kalispell Regional Medical Center Nestled in the beautiful Flathead Valley of Northwestern Montana, Kalispell Regional...
Click here to add this to my saved trials
Kansas City, Kansas 66160
Principal Investigator: Ajoy L. Dias
Phone: 913-945-7552
Click here to add this to my saved trials
Kennewick, Washington 99336
Principal Investigator: Alison K. Conlin
Phone: 509-783-4637
Click here to add this to my saved trials
Lacey, Washington 98503
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
Click here to add this to my saved trials
Lake Forest, Illinois 60045
Principal Investigator: Shira N. Dinner
Click here to add this to my saved trials
450 Lakeville Road
Lake Success, New York 11042
Lake Success, New York 11042
Principal Investigator: Cristina M. Ghiuzeli
Phone: 516-734-8896
Click here to add this to my saved trials
1215 E Michigan Ave
Lansing, Michigan 48912
Lansing, Michigan 48912
(517) 364-1000
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Sparrow Hospital Sparrow has grown to become the region's largest health system, and its diverse...
Click here to add this to my saved trials
325 Maine Street
Lawrence, Kansas 66044
Lawrence, Kansas 66044
(785) 505-5000
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Lawrence Memorial Hospital Lawrence Memorial Hospital (LMH), in collaboration with its medical staff, is dedicated...
Click here to add this to my saved trials
Livonia, Michigan 48154
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Longview, Washington 98632
Principal Investigator: Alison K. Conlin
Phone: 360-514-2016
Click here to add this to my saved trials